P A Lachenbruch

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Power and sample size requirements for two-part models
    P A Lachenbruch
    FDA CBER Office of Biostatistics and Epidemiology, Food and Drug Administration, Rockville, MD 20852, USA
    Stat Med 20:1235-8. 2001
  2. ncbi Comparisons of two-part models with competitors
    P A Lachenbruch
    FDA CBER Division of Biostatistics and Epidemiology, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852 1448, USA
    Stat Med 20:1215-34. 2001
  3. ncbi Lot consistency as an equivalence problem
    P A Lachenbruch
    U S FDA Center for Biologics Evaluation and Research, Rockville, Maryland 20852, USA
    J Biopharm Stat 14:275-90. 2004

Detail Information

Publications3

  1. ncbi Power and sample size requirements for two-part models
    P A Lachenbruch
    FDA CBER Office of Biostatistics and Epidemiology, Food and Drug Administration, Rockville, MD 20852, USA
    Stat Med 20:1235-8. 2001
    ..We derive sample size calculations. We note that some modifications of this procedure may provide better tests if the non-zero responses are discrete. Published in 2001 by John Wiley & Sons, Ltd...
  2. ncbi Comparisons of two-part models with competitors
    P A Lachenbruch
    FDA CBER Division of Biostatistics and Epidemiology, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852 1448, USA
    Stat Med 20:1215-34. 2001
    ..In those cases, the two-part models are not far behind, although statistically significantly poorer with respect to power. Published in 2001 by John Wiley & Sons, Ltd...
  3. ncbi Lot consistency as an equivalence problem
    P A Lachenbruch
    U S FDA Center for Biologics Evaluation and Research, Rockville, Maryland 20852, USA
    J Biopharm Stat 14:275-90. 2004
    ..It appears to detect departures from equivalence that are not reflected by differences among group means...